Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk’s Wegovy Gets EU Thumbs Up But Launch Will Wait

Based On Positive Phase III Data

Executive Summary

Wegovy is set to join Saxenda as the company’s second EU approved drug for obesity, helping it corner the region’s weight-management market, once the company gets its supply back on track.

You may also be interested in...



Novo Nordisk Enjoys Obesity Sales Boost Despite Wegovy Supply Issues

Novo Nordisk’s obesity product sales have soared against the odds as supply chain issues for recently approved Wegovy continued.

SynAct Surveys Its Options As Rheumatoid Arthritis Asset Succeeds At Phase II

The company’s lead candidate, AP1189, has shown promise in a mid-stage rheumatoid arthritis study, sparking plans for an imminent strategic business collaboration. 

NRx’s COVID-19 Vaccine Candidate BriLife Impresses In Phase II

NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145402

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel